格林國際控股(02700.HK)中期虧損984.4萬港元 同比收窄7.45%
格隆匯8月31日丨格林國際控股(02700.HK)發佈公吿,截至2022年6月30日止6個月,實現收益2503.7萬港元,同比減少31.42%;公司擁有人應占虧損984.4萬港元,同比收窄7.45%;基本每股虧損1.49港仙。
收入減少主要是由於經濟及營商環境存在變數以及中國消費市場疲軟。
集團保健及醫療業務分部透過澧縣鳳凰醫院有限公司及益陽子仲腎臟病醫院有限公司於中國湖南省經營其醫院業務。上述兩間營運公司均已取得國家衞生健康委員會地方部門授出醫療機構執業許可證,可經營(其中包括)血液透析治療等獲許可醫療。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.